<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00696774</url>
  </required_header>
  <id_info>
    <org_study_id>12349</org_study_id>
    <secondary_id>F1J-CR-S022</secondary_id>
    <nct_id>NCT00696774</nct_id>
  </id_info>
  <brief_title>Switching to Duloxetine in Patients With Depression</brief_title>
  <acronym>ARDENT</acronym>
  <official_title>Attributes of Response in Depressed Patients Switched to Treatment With Duloxetine (ARDENT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to help answer the following research question: Whether
      switching to duloxetine improves depressed mood when current treatment did not work well for
      patients with depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Brief Pain Inventory-Modified Short Form (BPI-SF) Interference Score Between Responder and Non-Responder Participants at 4 Weeks</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
    <description>BPI-SF interference score asks about the degree to which pain interferes with mood, walking and other physical activity, work, social activity, relations with others, and sleep. BPI-SF interference score ranges from 0 (no interference) to 10 (interferes completely). Response is defined as a &gt;=50% reduction in the Maier subscale score from baseline. The Maier subscale (Items 1,2,7,8,9,10) represents &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting Criteria for Response on the 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale at 4 and 8 Weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Response is defined as a &gt;=50% reduction in the Maier subscale score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline HAMD-17 Total Score at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The HAMD-17 total score measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline HAMD-17 Core Subscale at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The Core subscale (Items 1,2,3,7,8) evaluates &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 20 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline HAMD-17 Maier Subscale at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline HAMD-17 Anxiety/Somatization Subscale at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The Anxiety/Somatization Subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifistations of anxiety as well as agitation. Total subscale scores range from 0 (normal) to 18 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline HAMD-17 Retardation/Somatization Subscale at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The Retardation Subscale (Items 1,7,8,14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation. Total subscale scores range from 0 (normal) to 14 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline HAMD-17 Sleep Subscale at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The Sleep Subscale (Items 4,5,6) evaluates initial, middle, and late insomnia. Total subscale scores range from 0 (no difficulty) to 6 (difficulty). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Hamilton Anxiety Rating Scale (HAMA) at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The HAMA scale measures anxiety symptoms accompanying major depressive disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56. Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinical Global Impression - Severity (CGI-Severity) Scale at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Brief Pain Inventory - Modified Short Form (BPI-SF) Average Pain Score at 8 Weeks</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Impression - Improvement (PGI-I) Scale Score at 8 Weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Sexual Functioning Questionnaire Clinical Version (CSFQ) at 4 and 8 Weeks</measure>
    <time_frame>Baseline, 4 Weeks, 8 weeks</time_frame>
    <description>A 14-item patient-rated scale assesses medication-related changes in sexual activity/functioning. Items rated from 1 (never, low enjoyment/pleasure) to 5 (every day, great enjoyment/pleasure). CSFQ measures 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Lower total scores are associated with diminished sexual functioning. Total scores &lt;=47 (men) and &lt;=41 (women) indicate global sexual dysfunction, with all phases of sexual response cycle affected. Factors used for adjustment for least squares means are in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) at 4 and 8 Weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>The TSQM is a participant-reported measure that best describes how the study medication makes them feel since the last study visit, assessing perceived effectiveness, severity of side effects, and convenience. Convenience, Effectiveness, Side-Effects, and Global Satisfaction scale scores range from 0 (extremely dissatisfied) to 100 (extremely satisfied). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Sheehan Disability Scale (SDS) at 4 and 8 Weeks</measure>
    <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
    <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Depressive Disorder, Major</condition>
  <arm_group>
    <arm_group_label>Duloxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who met criteria in Study Period I (screening) were treated with duloxetine 60 milligrams (mg) once daily (QD) in an open-label manner for 4 weeks (Study Period II). Study Period II was considered the acute therapy period. Study Period III was a 4-week interval where patients who did not respond during Study Period II had their duloxetine doses optimized to 120 mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.
Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.</description>
    <arm_group_label>Duloxetine</arm_group_label>
    <other_name>LY248686</other_name>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients aged 18 years or older who meet criteria for Major
             Depressive Disorder (MDD).

          -  Currently receiving a selective serotonin reuptake inhibitor (SSRI) or a
             serotonin-norepinephrine reuptake inhibitor (SNRI) class of antidepressant for at
             least a month for the treatment of depression.

          -  Females of child-bearing potential (not surgically sterilized and between menarche and
             1 year postmenopause) to test negative for pregnancy based on a urine pregnancy test
             and to agree to use a reliable method of birth control.

        Exclusion Criteria:

          -  Women who are pregnant or plan to be pregnant or are breastfeeding.

          -  To have received treatment within the last 30 days with a drug that has not received
             regulatory approval for any indication.

          -  Diagnosed with treatment resistant depression.

          -  History of bipolar disorder, schizophrenia, or other psychotic disorders.

          -  To have previously taken duloxetine that didn't work.

          -  Judged to be at serious suicidal risk in the opinion of the investigator and/or score
             &gt;=3 on Item 3 (suicide) of the 17-Item Hamilton Depression Rating Scale (HAMD-17) at
             screening (Visit 1) or baseline (Visit 2).

          -  A serious medical illness that may need treatment during the study.

          -  Taking certain medications that are not allowed in this study.

          -  To have a history of alcohol and/or drug abuse or dependence within the past year.

          -  To have uncontrolled narrow-angle glaucoma.

          -  To have allergic reactions to many medicines.

          -  To have undergone &quot;shock&quot; therapy (Electroconvulsive Therapy) or &quot;magnet&quot; treatment
             (Transcranial Magnetic Stimulation) within the past year.

          -  To initiate &quot;talk therapy&quot; (psychotherapy) just before or during the study.

          -  To have chronic pain and you have been taking medicine for it for the last 6 months.

          -  To have certain liver diseases.

          -  To have kidney disease or undergoing dialysis.

          -  Abnormal thyroid stimulating hormone (TSH) concentration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Guri City</city>
        <zip>471-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seoul</city>
        <zip>136 705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>China</country>
  </removed_countries>
  <link>
    <url>http://www.lillytrials.com</url>
    <description>Lilly Clinical Trial Registry</description>
  </link>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2008</study_first_posted>
  <results_first_submitted>July 15, 2010</results_first_submitted>
  <results_first_submitted_qc>July 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 11, 2010</results_first_posted>
  <last_update_submitted>September 2, 2010</last_update_submitted>
  <last_update_submitted_qc>September 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Eli Lilly</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>270 participants began the study. 26 were screen failures (17 did not meet entry criteria, 7 decided to withdraw, and 2 withdrew based on the physician's decision). 2 participants discontinued before enrollment (1 was lost to follow-up and 1 decided to withdraw).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Responders</title>
          <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
        </group>
        <group group_id="P2">
          <title>Non-Responders</title>
          <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-Responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
        </group>
        <group group_id="P3">
          <title>Unclassified</title>
          <description>Participants who received 60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II) with unknown response status.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="36">1 participant did not receive study drug and was not included in the safety analyses.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period III</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113">115 reported at Week 4; 113 started Period 3 (1 lost to follow-up and 1 protocol violation).</participants>
                <participants group_id="P2" count="88">91 reported at Week 4; 88 start Period 3 (1 adverse event, 1 protocol violation, 1 lack of efficacy)</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="81">82 participants were reported at Week 8; 81 completed Week 8 as 1 participant decided to withdraw.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Duloxetine Responders</title>
          <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
        </group>
        <group group_id="B2">
          <title>Duloxetine Non-Responders</title>
          <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
        </group>
        <group group_id="B3">
          <title>Unclassified</title>
          <description>Participants who received 60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II) with unknown response status.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="36"/>
            <count group_id="B4" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="12.9"/>
                    <measurement group_id="B2" value="45.6" spread="12.5"/>
                    <measurement group_id="B3" value="47.4" spread="10.6"/>
                    <measurement group_id="B4" value="44.9" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>East Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>West Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had Major Depressive Disorder (MDD) Hospitalizations in the Past 24 Months</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had Previous MDD in the Past 24 Months</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had at Least One Historical Illness</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Treatment</title>
          <description>Previous selective serotonin reuptake inhibitor (SSRI) or serotonin norepinephrine reuptake inhibitor (SNRI) treatment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>SSRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SNRI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing or Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-Item Hamilton Depression Rating Scale (HAMD-17) Anxiety/Somatization Score</title>
          <description>The Anxiety/Somatization Subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifestations of anxiety as well as agitation. Total subscale scores range from 0 (normal) to 18 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.7" spread="2.1"/>
                    <measurement group_id="B2" value="8.0" spread="2.0"/>
                    <measurement group_id="B3" value="7.4" spread="1.7"/>
                    <measurement group_id="B4" value="7.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-Item Hamilton Depression Rating Scale (HAMD-17) Core Score</title>
          <description>The Core subscale (Items 1,2,3,7,8) evaluates &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 20 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.1" spread="2.6"/>
                    <measurement group_id="B2" value="9.0" spread="2.6"/>
                    <measurement group_id="B3" value="7.9" spread="2.8"/>
                    <measurement group_id="B4" value="8.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Score</title>
          <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="2.6"/>
                    <measurement group_id="B2" value="11.7" spread="2.6"/>
                    <measurement group_id="B3" value="10.0" spread="2.7"/>
                    <measurement group_id="B4" value="11.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-Item Hamilton Depression Rating Scale (HAMD-17) Retardation Score</title>
          <description>The Retardation Subscale (Items 1,7,8,14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation. Total subscale scores range from 0 (normal) to 14 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.1" spread="2.1"/>
                    <measurement group_id="B2" value="8.2" spread="1.9"/>
                    <measurement group_id="B3" value="7.2" spread="2.4"/>
                    <measurement group_id="B4" value="7.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-Item Hamilton Depression Rating Scale (HAMD-17) Sleep Score</title>
          <description>The Sleep Subscale (Items 4,5,6) evaluates initial, middle, and late insomnia. Total subscale scores range from 0 (no difficulty) to 6 (difficulty).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.1" spread="1.6"/>
                    <measurement group_id="B2" value="3.4" spread="1.4"/>
                    <measurement group_id="B3" value="3.2" spread="1.7"/>
                    <measurement group_id="B4" value="3.2" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>17-Item Hamilton Depression Rating Scale (HAMD-17) Total Score</title>
          <description>The HAMD-17 measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="4.5"/>
                    <measurement group_id="B2" value="23.3" spread="4.5"/>
                    <measurement group_id="B3" value="20.7" spread="4.5"/>
                    <measurement group_id="B4" value="21.9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age of First Episode of MDD</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="11.7"/>
                    <measurement group_id="B2" value="33.5" spread="13.6"/>
                    <measurement group_id="B3" value="36.9" spread="12.8"/>
                    <measurement group_id="B4" value="34.8" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Pain Inventory - Short Form (BPI-SF) Average Pain Score</title>
          <description>A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.7" spread="1.9"/>
                    <measurement group_id="B2" value="5.0" spread="2.0"/>
                    <measurement group_id="B3" value="4.4" spread="2.2"/>
                    <measurement group_id="B4" value="4.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brief Pain Inventory - Short Form Interference Score</title>
          <description>The BPI-SF interference score asks about the degree to which pain interferes with mood, walking and other physical activity, work, social activity, relations with others, and sleep. BPI-SF interference score ranges from 0 (no interference) to 10 (interferes completely).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="1.6"/>
                    <measurement group_id="B2" value="5.9" spread="1.8"/>
                    <measurement group_id="B3" value="5.2" spread="1.9"/>
                    <measurement group_id="B4" value="5.5" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Changes in Sexual Function Questionnaire (CSFQ)</title>
          <description>A 14-item patient-rated scale designed to assess medication-related changes in sexual activity/functioning. Items are rated from 1 (never, low enjoyment or pleasure) to 5 (every day/great enjoyment or pleasure). CSFQ measures 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. CSFQ total score is obtained across all 5 dimensions. Lower scores are associated with sexual dysfunction/diminished sexual functioning. Total scores &lt;=47 (men) and &lt;=41 (women) indicate global sexual dysfunction, with all phases of the sexual response cycle being affected.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="10.3"/>
                    <measurement group_id="B2" value="35.4" spread="9.8"/>
                    <measurement group_id="B3" value="33.8" spread="9.4"/>
                    <measurement group_id="B4" value="35.1" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions - Severity (CGI-Severity) Score</title>
          <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="0.6"/>
                    <measurement group_id="B2" value="4.4" spread="0.6"/>
                    <measurement group_id="B3" value="4.3" spread="0.7"/>
                    <measurement group_id="B4" value="4.3" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of the Current Episode</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="249.4" spread="378.3"/>
                    <measurement group_id="B2" value="264.5" spread="318.1"/>
                    <measurement group_id="B3" value="194.1" spread="182.6"/>
                    <measurement group_id="B4" value="247.3" spread="333.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hamilton Anxiety Rating Scale (HAMA) Total Score</title>
          <description>The HAMA scale measures anxiety symptoms accompanying major depressive disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.9" spread="6.8"/>
                    <measurement group_id="B2" value="21.4" spread="6.8"/>
                    <measurement group_id="B3" value="17.9" spread="7.6"/>
                    <measurement group_id="B4" value="19.2" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of MDD Hospitalizations in the Past 24 Months</title>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.0" spread="0.0"/>
                    <measurement group_id="B2" value="1.0" spread="0.0"/>
                    <measurement group_id="B3" value="1.0" spread="0.0"/>
                    <measurement group_id="B4" value="1.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Previous MDD Episodes in the Past 24 Months</title>
          <units>MDD episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.8"/>
                    <measurement group_id="B2" value="1.5" spread="0.7"/>
                    <measurement group_id="B3" value="1.8" spread="1.5"/>
                    <measurement group_id="B4" value="1.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sheehan Disability Scale (SDS)</title>
          <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" spread="2.9"/>
                    <measurement group_id="B2" value="6.3" spread="3.0"/>
                    <measurement group_id="B3" value="5.5" spread="3.0"/>
                    <measurement group_id="B4" value="5.7" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Treatment Satisfaction Questionnaire for Medication (TSQM)</title>
          <description>The TSQM is a participant-reported measure that best describes how the study medication makes them feel since the last study visit, assessing perceived effectiveness, severity of side effects, and convenience. Convenience, Effectiveness, Side-Effects, and Global Satisfaction scale scores range from 0 (extremely dissatisfied) to 100 (extremely satisfied).</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="17.6"/>
                    <measurement group_id="B2" value="41.6" spread="18.2"/>
                    <measurement group_id="B3" value="47.2" spread="20.8"/>
                    <measurement group_id="B4" value="43.7" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Brief Pain Inventory-Modified Short Form (BPI-SF) Interference Score Between Responder and Non-Responder Participants at 4 Weeks</title>
        <description>BPI-SF interference score asks about the degree to which pain interferes with mood, walking and other physical activity, work, social activity, relations with others, and sleep. BPI-SF interference score ranges from 0 (no interference) to 10 (interferes completely). Response is defined as a &gt;=50% reduction in the Maier subscale score from baseline. The Maier subscale (Items 1,2,7,8,9,10) represents &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 4 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Brief Pain Inventory-Modified Short Form (BPI-SF) Interference Score Between Responder and Non-Responder Participants at 4 Weeks</title>
          <description>BPI-SF interference score asks about the degree to which pain interferes with mood, walking and other physical activity, work, social activity, relations with others, and sleep. BPI-SF interference score ranges from 0 (no interference) to 10 (interferes completely). Response is defined as a &gt;=50% reduction in the Maier subscale score from baseline. The Maier subscale (Items 1,2,7,8,9,10) represents &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.35" lower_limit="-2.83" upper_limit="-1.87"/>
                    <measurement group_id="O2" value="-1.69" lower_limit="-2.18" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Adjusted Repeated Measures Analysis</method>
            <method_desc>Model terms: baseline score &amp; CGI, age, sex, country, prev treatment, prev treatment discontinuation reason, response group, visit &amp; response-by-visit</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.66</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting Criteria for Response on the 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale at 4 and 8 Weeks</title>
        <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Response is defined as a &gt;=50% reduction in the Maier subscale score from baseline.</description>
        <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks. Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting Criteria for Response on the 17-Item Hamilton Depression Rating Scale (HAMD-17) Maier Subscale at 4 and 8 Weeks</title>
          <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Response is defined as a &gt;=50% reduction in the Maier subscale score from baseline.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=193)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="48.7" upper_limit="63.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" lower_limit="66.7" upper_limit="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline HAMD-17 Total Score at 8 Weeks</title>
        <description>The HAMD-17 total score measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline HAMD-17 Total Score at 8 Weeks</title>
          <description>The HAMD-17 total score measures depression severity. Each item was evaluated and scored using either a 5-point scale (e.g. absent, mild, moderate, severe, very severe) or a 3-point scale (e.g. absent, mild, marked). The total score of HAMD-17 may range from 0 (normal) to 52 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.64" lower_limit="-16.86" upper_limit="-14.41"/>
                    <measurement group_id="O2" value="-9.79" lower_limit="-11.10" upper_limit="-8.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.34</ci_lower_limit>
            <ci_upper_limit>-4.36</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline HAMD-17 Core Subscale at 8 Weeks</title>
        <description>The Core subscale (Items 1,2,3,7,8) evaluates &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 20 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline HAMD-17 Core Subscale at 8 Weeks</title>
          <description>The Core subscale (Items 1,2,3,7,8) evaluates &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 20 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.87" lower_limit="-7.41" upper_limit="-6.33"/>
                    <measurement group_id="O2" value="-4.40" lower_limit="-4.99" upper_limit="-3.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.13</ci_lower_limit>
            <ci_upper_limit>-1.81</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline HAMD-17 Maier Subscale at 8 Weeks</title>
        <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline HAMD-17 Maier Subscale at 8 Weeks</title>
          <description>The Maier subscale (Items 1,2,7,8,9,10) represents the &quot;core&quot; symptoms of depression. Total subscale scores range from 0 (normal) to 24 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.58" lower_limit="-9.25" upper_limit="-7.90"/>
                    <measurement group_id="O2" value="-5.29" lower_limit="-6.01" upper_limit="-4.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.10</ci_lower_limit>
            <ci_upper_limit>-2.48</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline HAMD-17 Anxiety/Somatization Subscale at 8 Weeks</title>
        <description>The Anxiety/Somatization Subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifistations of anxiety as well as agitation. Total subscale scores range from 0 (normal) to 18 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline HAMD-17 Anxiety/Somatization Subscale at 8 Weeks</title>
          <description>The Anxiety/Somatization Subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifistations of anxiety as well as agitation. Total subscale scores range from 0 (normal) to 18 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.29" lower_limit="-5.84" upper_limit="-4.73"/>
                    <measurement group_id="O2" value="-3.07" lower_limit="-3.68" upper_limit="-2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.89</ci_lower_limit>
            <ci_upper_limit>-1.54</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline HAMD-17 Retardation/Somatization Subscale at 8 Weeks</title>
        <description>The Retardation Subscale (Items 1,7,8,14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation. Total subscale scores range from 0 (normal) to 14 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline HAMD-17 Retardation/Somatization Subscale at 8 Weeks</title>
          <description>The Retardation Subscale (Items 1,7,8,14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation. Total subscale scores range from 0 (normal) to 14 (severe). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.51" lower_limit="-5.98" upper_limit="-5.05"/>
                    <measurement group_id="O2" value="-3.63" lower_limit="-4.14" upper_limit="-3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.45</ci_lower_limit>
            <ci_upper_limit>-1.30</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline HAMD-17 Sleep Subscale at 8 Weeks</title>
        <description>The Sleep Subscale (Items 4,5,6) evaluates initial, middle, and late insomnia. Total subscale scores range from 0 (no difficulty) to 6 (difficulty). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline HAMD-17 Sleep Subscale at 8 Weeks</title>
          <description>The Sleep Subscale (Items 4,5,6) evaluates initial, middle, and late insomnia. Total subscale scores range from 0 (no difficulty) to 6 (difficulty). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.27" lower_limit="-2.59" upper_limit="-1.96"/>
                    <measurement group_id="O2" value="-1.31" lower_limit="-1.64" upper_limit="-0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.31</ci_lower_limit>
            <ci_upper_limit>-0.63</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Hamilton Anxiety Rating Scale (HAMA) at 8 Weeks</title>
        <description>The HAMA scale measures anxiety symptoms accompanying major depressive disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56. Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Hamilton Anxiety Rating Scale (HAMA) at 8 Weeks</title>
          <description>The HAMA scale measures anxiety symptoms accompanying major depressive disorder (MDD). Each item of the 14-item HAMA was scored from 0 (not present) to 4 (very severe), with a resulting maximum total score of 56. Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.97" lower_limit="-14.37" upper_limit="-11.56"/>
                    <measurement group_id="O2" value="-8.55" lower_limit="-10.04" upper_limit="-7.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.04</ci_lower_limit>
            <ci_upper_limit>-2.80</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinical Global Impression  Severity (CGI-Severity) Scale at 8 Weeks</title>
        <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinical Global Impression  Severity (CGI-Severity) Scale at 8 Weeks</title>
          <description>Measures severity of illness at the time of assessment compared with start of treatment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.52" lower_limit="-2.75" upper_limit="-2.30"/>
                    <measurement group_id="O2" value="-1.40" lower_limit="-1.65" upper_limit="-1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.42</ci_lower_limit>
            <ci_upper_limit>-0.84</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Brief Pain Inventory - Modified Short Form (BPI-SF) Average Pain Score at 8 Weeks</title>
        <description>A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Brief Pain Inventory - Modified Short Form (BPI-SF) Average Pain Score at 8 Weeks</title>
          <description>A self-reported scale that measures the severity of pain based on the average pain experienced over the past 24-hours. The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" lower_limit="-3.13" upper_limit="-1.99"/>
                    <measurement group_id="O2" value="-2.14" lower_limit="-2.75" upper_limit="-1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.08</ci_lower_limit>
            <ci_upper_limit>-0.24</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Impression - Improvement (PGII) Scale Score at 8 Weeks</title>
        <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Impression - Improvement (PGII) Scale Score at 8 Weeks</title>
          <description>A scale that measures the patient's perception of improvement at the time of assessment compared with the start of treatment. The score ranges from 1 (very much better) to 7 (very much worse). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.85" upper_limit="2.38"/>
                    <measurement group_id="O2" value="2.61" lower_limit="2.33" upper_limit="2.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Sexual Functioning Questionnaire Clinical Version (CSFQ) at 4 and 8 Weeks</title>
        <description>A 14-item patient-rated scale assesses medication-related changes in sexual activity/functioning. Items rated from 1 (never, low enjoyment/pleasure) to 5 (every day, great enjoyment/pleasure). CSFQ measures 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Lower total scores are associated with diminished sexual functioning. Total scores &lt;=47 (men) and &lt;=41 (women) indicate global sexual dysfunction, with all phases of sexual response cycle affected. Factors used for adjustment for least squares means are in 'Other relevant information' section.</description>
        <time_frame>Baseline, 4 Weeks, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Sexual Functioning Questionnaire Clinical Version (CSFQ) at 4 and 8 Weeks</title>
          <description>A 14-item patient-rated scale assesses medication-related changes in sexual activity/functioning. Items rated from 1 (never, low enjoyment/pleasure) to 5 (every day, great enjoyment/pleasure). CSFQ measures 5 dimensions of sexual behavior: pleasure; desire/frequency; desire/interest; arousal; orgasm. Lower total scores are associated with diminished sexual functioning. Total scores &lt;=47 (men) and &lt;=41 (women) indicate global sexual dysfunction, with all phases of sexual response cycle affected. Factors used for adjustment for least squares means are in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" lower_limit="-1.84" upper_limit="1.90"/>
                    <measurement group_id="O2" value="-0.78" lower_limit="-2.76" upper_limit="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="-0.90" upper_limit="3.05"/>
                    <measurement group_id="O2" value="-0.29" lower_limit="-2.42" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.99</ci_lower_limit>
            <ci_upper_limit>2.60</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>3.42</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) at 4 and 8 Weeks</title>
        <description>The TSQM is a participant-reported measure that best describes how the study medication makes them feel since the last study visit, assessing perceived effectiveness, severity of side effects, and convenience. Convenience, Effectiveness, Side-Effects, and Global Satisfaction scale scores range from 0 (extremely dissatisfied) to 100 (extremely satisfied). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM) at 4 and 8 Weeks</title>
          <description>The TSQM is a participant-reported measure that best describes how the study medication makes them feel since the last study visit, assessing perceived effectiveness, severity of side effects, and convenience. Convenience, Effectiveness, Side-Effects, and Global Satisfaction scale scores range from 0 (extremely dissatisfied) to 100 (extremely satisfied). Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.64" lower_limit="12.88" upper_limit="22.39"/>
                    <measurement group_id="O2" value="2.59" lower_limit="-2.16" upper_limit="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.67" lower_limit="13.37" upper_limit="23.97"/>
                    <measurement group_id="O2" value="8.19" lower_limit="2.65" upper_limit="13.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>10.63</ci_lower_limit>
            <ci_upper_limit>19.47</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>10.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.72</ci_lower_limit>
            <ci_upper_limit>16.24</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Sheehan Disability Scale (SDS) at 4 and 8 Weeks</title>
        <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
        <time_frame>Baseline, 4 weeks, 8 weeks</time_frame>
        <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Duloxetine Responders</title>
            <description>60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
          <group group_id="O2">
            <title>Duloxetine Non-Responders</title>
            <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Sheehan Disability Scale (SDS) at 4 and 8 Weeks</title>
          <description>The SDS is completed by the patient and is used to assess the effect of the patient's symptoms on their work/social/family life. Total scores range from 0 to 30 with higher values indicating greater disruption in the patient's work/social/family life. Factors used for adjustment for least squares means are listed in 'Other relevant information' section.</description>
          <population>Efficacy Population: Participants who had at least one post-baseline observation were included in the efficacy analysis. The group &quot;Unclassified&quot; was excluded from statistical testing.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.38" lower_limit="-10.26" upper_limit="-6.50"/>
                    <measurement group_id="O2" value="-2.49" lower_limit="-4.42" upper_limit="-0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.95" lower_limit="-11.91" upper_limit="-7.99"/>
                    <measurement group_id="O2" value="-5.36" lower_limit="-7.40" upper_limit="-3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.75</ci_lower_limit>
            <ci_upper_limit>-4.02</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.65</ci_lower_limit>
            <ci_upper_limit>-2.54</ci_upper_limit>
            <estimate_desc>Least Squares Mean Difference = Responders - Non-Responders.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Duloxetine Responders</title>
          <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Responder group - 60 mg capsules, QD, for 4 weeks more (Study Period III).</description>
        </group>
        <group group_id="E2">
          <title>Duloxetine Non-Responders</title>
          <description>60 mg duloxetine capsules, QD, for 4 weeks (Study Period II). Non-Responder group - 120 mg capsules, QD, for 4 weeks more (Study Period III).</description>
        </group>
        <group group_id="E3">
          <title>Unclassified</title>
          <description>Participants who received 60 milligram (mg) duloxetine capsules, once daily (QD), for 4 weeks (Study Period II) with unknown response status.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="91"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="91"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="115"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="91"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="91"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

